mPEG-PLGA from PolySciTech Used in Development of anti-TNF-alpha therapy for Crohn’s disease treatment.

 

Crohn’s disease is a chronic inflammatory bowel disease caused by over immune response. Researchers at Johns Hopkins University used PEG-PLGA (AK106) ) from PolySciTech Division of Akina, Inc. (www.polyscitech.com) to develop nanoparticles which deliver monoclonal antibodies for anti-TNF-alpha which reduces pro-inflammatory cytokines and signals the body to take a less aggressive immune response. This research holds promise to improve treatment of IBS. Read more: Zhang, Yicheng, Ling Li, Jiayuan Kong, Yuanmuhuang Long, Xiaoya Lu, Christopher J. Erb, Yurun Miao et al. "Long-acting injectable nanoparticle formulation for sustained release of anti-TNF-α antibody therapeutic in ulcerative colitis treatment." Journal of Controlled Release 380 (2025): 1005-1016. https://www.sciencedirect.com/science/article/pii/S0168365925001567

“Inflammatory bowel diseases (IBD) are chronic, remitting, and relapsing conditions of the gastrointestinal tract with incompletely elucidated etiology. The anti-TNF-α mAbs represent one of aflash nanocomplexation and flash nanoprecipitation process, resulting in particles with a narrow size distribution and tunable release profile, with the longest in vitro release lasting over four months. These mAb-releasing NPs are then incorporated into hyaluronic acid hydrogel microparticles (MPs) to enhance tissue retention, thus extending the duration of mAb release in vivo. A single i.m. injection of the LAI can maintain the serum mAb level above the therapeutically effective concentration for over 100 days in healthy mice. In a 9-week study using a dextran sulfate-induced chronic colitis model, the anti-TNF-α LAI formulation demonstrates substantial therapeutic efficacy and a better safety profile than free mAb injections. This work demonstrates the effectiveness of this LAI system in maintaining a persistent serum mAb level and its potential as a versatile, safer, and effective delivery system for antibody therapeutics.”

mPEG-PLGA (Cat# AK106): https://akinainc.com/polyscitech/products/polyvivo/index.php?highlight=AK106#h

Akina, Inc. launches new GMP manufacturing service available to outside customers https://www.akinainc.com/midwestgmp/

Corbion Purasorb® Polymers: https://akinainc.com/polyscitech/products/purasorb/

Ashland-TM Polymer Products: https://akinainc.com/polyscitech/products/ashland/